BIOPHEN™ DTI (220202) is a Chromogenic method for Direct Thrombin Inhibitors (DTI) assay. Manufactured by HYPHEN BioMed.
BIOPHEN™ DTI is a chromogenic method based on the inhibition of a constant and in excess amount of thrombin (FIIa), by the tested Dabigatran or DTI. The hydrolysis of a thrombin specific chromogenic substrate (CS-01(81)), by the residual thrombin, releases the pNA from the substrate. The amount of pNA released (measured at 405 nm) is proportional to the residual thrombin activity. There is an inverse linear relationship between the concentration of Dabigatran (or DTI) and color development. [DTI] + [FIIa (excess)] [FIIa-DTI] + [residual FIIa] [FIIa (residual)] + Substrate Peptide + pNA